法人情報

お気に入りページ登録に失敗しました
お気に入りページ解除に失敗しました
すでにお気に入り登録済みのページです
自社はお気に入り登録できません

最終更新日時: 2021/04/21 11:44:51

Nathiasu Co., Ltd.

The core of our business is large-scale synthesizing technology for nucleic acid 

We possess mass production technology that allows the reduction of production cost when producing high purity nucleic acid bulk drugs. We sell nucleic acid drug substance manufacturing equipment that we have jointly developed with a Japanese manufacturer and academic support drug discovery researchers.

お問い合わせ
メイン画像

アピールポイント

We make nucleotide drug substances for patients suffering from illness.
Nucleic acid drug substance manufacturing equipment
We have produced a prototype of a nucleic acid bulk drug manufacturing device as a commissioned project from The Japan Agency for Medical Research and Development (AMED). This device is highly productive, and we are continuing the development toward commercialization in collaboration with a Japanese device manufacturer.
This is a device with high performance. The purity of its product is over 90% even without refinement. (The product purities of competing devices are about 70%, and about 90% even after refinement).
Nucleic acid drug substance-free provision business
We provide the nucleic acid drug substances that are produced during manufacturing tests of the nucleic acid drug substance manufacturing equipment to academia for free to support drug discovery research and work toward the expansion of the Japanese nucleic acid drug substance market. 
Application of our technology to commercial manufacturing equipment
The materials for nucleic acid drug substance manufacturing that we have developed can also yield great results when used with commercial manufacturing devices.  Once one of the developed raw materials is changed and used once, the purity of the bulk drug will be dramatically improved. We contribute to the vitalization of the nucleic acid drug substance market by providing our materials to existing nucleic acid drug substance manufacturing companies. 
Monitoring the manufacture of hexamer intermediates
The Blockmer material that we have developed is produced quickly using a liquid‐phase method. The hexamer material is easily produced from two trimer materials that are prepared in advance. The nucleic acid drug substance is manufactured by repeating this process.
Monitoring of block chain length extension process
Our liquid-phase method that uses Blockmer raw materials makes it possible to extend to the target chain length in two steps. As the manufacturing process can be monitored, it is produced using the same process as a small-molecule drug although it is a macromolecule.
Example of manufacturing a small molecule nucleotide drug by phosphorylation technology
We accept orders for the development of manufacturing technology for low molecular nucleotide drugs for generic manufacturers. 
By utilizing the technology we own, we have managed to significantly reduce the steps and waste involved in the process.

この企業は以下の支援機関から推薦されています

Marketing Support Department, SMRJ
お問い合わせ